Video

Dr. Noel on the Impact of SM-88 in Pancreatic Cancer

Author(s):

Marcus Noel, MD, discusses the data of SM-88 and how it will impact the treatment of patients with metastatic pancreatic cancer.

Marcus Noel, MD, assistant professor, Department of Medicine, Hematology/Oncology, University of Rochester Medical Center, discusses the data of SM-88 and how it will impact the treatment of patients with metastatic pancreatic cancer.

The premise of SM-88, which consists of a tyrosine derivative (D,L-alpha-metyrosine), an mTOR inhibitor (sirolimus), a CYP3a4 inducer (phenytoin), and an oxidative stress catalyst (methoxsalen), is to interfere with cancer metabolism while keeping toxicities down, Noel says. The results have shown that the regimen is generally well tolerated and fits into the third-line setting.

Results of the single-arm, 2-part, phase II Tyme-88-Panc study presented at the 2019 Gastrointestinal Cancers Symposium demonstrated that SM-88 has promising efficacy in patients with metastatic pancreatic cancer who have progressed on at least 1 prior line of therapy.

The part 1 data showed that, at a median follow-up of 4.3 months after treatment initiation, 67.8% of 28 evaluable patients were still alive as of December 31, 2018. Survival status is ongoing, and the primary endpoint is response rate determined by blind independent central review.

View more from the 2019 Gastrointestinal Cancers Symposium

Related Videos
Albert Grinshpun, MD, MSc, head, Breast Oncology Service, Shaare Zedek Medical Center
Erica L. Mayer, MD, MPH, director, clinical research, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School
Stephanie Graff, MD, and Chandler Park, FACP
Mariya Rozenblit, MD, assistant professor, medicine (medical oncology), Yale School of Medicine
Maxwell Lloyd, MD, clinical fellow, medicine, Department of Medicine, Beth Israel Deaconess Medical Center
Neil Iyengar, MD, and Chandler Park, MD, FACP
Azka Ali, MD, medical oncologist, Cleveland Clinic Taussig Cancer Institute
Rena Callahan, MD, and Chandler Park, MD, FACP
Hope S. Rugo, MD, FASCO, Winterhof Family Endowed Professor in Breast Cancer, professor, Department of Medicine (Hematology/Oncology), director, Breast Oncology and Clinical Trials Education; medical director, Cancer Infusion Services; the University of California San Francisco Helen Diller Family Comprehensive Cancer Center
Virginia Kaklamani, MD, DSc, professor, medicine, Division of Hematology-Medical Oncology, The University of Texas (UT) Health Science Center San Antonio; leader, breast cancer program, Mays Cancer Center, UT Health San Antonio MD Anderson Cancer Center